Compare Cintas Corporation (CTAS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Cintas Corporation trades at $205.14 (market cap $82.15B), while Zimmer Biomet Holdings Inc trades at $96.14 (market cap $18.55B). The key difference: Cintas Corporation is far larger — about 4.4× Zimmer Biomet Holdings Inc's market cap, and Cintas Corporation pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| CTAS | ZBH | |
|---|---|---|
Market Cap | $82.15B | $18.55B |
Sector | Industrials | Health |
52-Week High | $225.10 | $107.71 |
52-Week Low | $163.55 | $79.58 |
Enterprise Value | $84.56B | $25.61B |
Dividend Yield | 1.01% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTAS trades at $203.06, showing modest daily gains. The stock exhibits a bullish technical trend, supported by recent earnings beats and strong profitability metrics, including a 17.75% net income margin. Recent news highlights dividend declarations and positive analyst upgrades following Q4 2026 results.
The outlook is positive, with revenue growth and margin expansion driving upside potential toward the $225.83 consensus price target. Risks include elevated valuation multiples and macroeconomic sensitivity. Institutional activity shows mixed positioning, but overall sentiment leans bullish.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
